Debra Remley
Psychiatric/Mental Health, Adult · Newport, MINPI 1548592249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,363, more than ten times the $11 reported in 2021.
Across 138 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$447
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$430
- Vanda Pharmaceuticals Inc.$383
- Otsuka America Pharmaceutical, Inc.$262
- Alkermes, Inc.$257
- Neurocrine Biosciences, Inc.$200
- plus $872 from 11 others
What the payments were for
- Food & beverage$2,79798%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $447 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $430 |
| Vanda Pharmaceuticals Inc. | 13 | $383 |
| Otsuka America Pharmaceutical, Inc. | 12 | $262 |
| Alkermes, Inc. | 10 | $257 |
| Neurocrine Biosciences, Inc. | 8 | $200 |
| Axsome Therapeutics, Inc. | 8 | $182 |
| Teva Pharmaceuticals USA, Inc. | 9 | $167 |
| E.r. Squibb & Sons, L.L.C. | 11 | $153 |
| Lundbeck LLC | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Johnson & Johnson | 4 | $65 |
| Sage Therapeutics, LLC | 3 | $64 |
| Corium, LLC | 1 | $33 |
| Eisai Inc. | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Neuronetics, Inc. | 1 | $11 |
How this compares
Too few psychiatric/mental health, adult providers in Michiganto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 43 | $99,991 |
| TrintellixVortioxetine Hydrobromide | 39 | $41,937 |
| VraylarCariprazine Hcl | 13 | $18,032 |
| Lurasidone Hcl | 60 | $11,642 |
| Paliperidone ErPaliperidone | 36 | $6,357 |
| Duloxetine Hcl | 286 | $6,278 |
| Quetiapine Fumarate | 211 | $5,298 |
| Aripiprazole | 114 | $3,813 |
| Lamotrigine | 317 | $3,580 |
| Oxcarbazepine | 89 | $2,779 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $2,536 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 128 | $2,428 |
| Trazodone Hcl | 232 | $2,141 |
| Bupropion Hcl SrBupropion Hcl | 77 | $1,514 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $262 | $99,99143 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $74 | $41,93739 claims |
| AbbVieVraylar | $447 | $18,03213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Michiganon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Newport
- Morgan BowenMason$4K
- Shari NussdorferMason$3K
- Gianina CristiuDetroit$3K
- Tracy BosankoLivonia$2K
- Josephine GriderBingham Farms$1K
- Melissa BlackLansing$907
- Melissa HinkhouseGwinn$876
- Shelly LerchHastings$832
- Krista BedellsMason$405
- Maryanne SwansonAnn Arbor$397
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.